In the TCGA-LIHC cohort, the expression levels and risk scores of STC2 and BIRC5 were positively correlated with the expression level of PDL1 (Figures 8A, B, E, F), indicated that both STC2 and BIRC5 can promote the expression of PDL1 on cancer cells, thereby promoting tumor immune escape. This evidence concerns the gene STC2 and cancer.